Clinical Trial Update: A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer [Phase 2]

View source ↗

Summary

A Phase II trial evaluating the combination of OSI-906 (linsitinib) and sorafenib in advanced hepatocellular carcinoma was terminated, with results posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Linsitinib (OSI-906) (linsitinib)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Emory University | Conditions: Liver Cancer | Phase 2 | Status: TERMINATED | Results posted: 2012-10-12